Ryu Jeong-Am, Yang Jeong Hoon, Lee Daesang, Park Chi-Min, Suh Gee Young, Jeon Kyeongman, Cho Joongbum, Baek Sun Young, Carriere Keumhee C, Chung Chi Ryang
Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
PLoS One. 2015 Sep 14;10(9):e0138150. doi: 10.1371/journal.pone.0138150. eCollection 2015.
Sepsis is a major cause of mortality and morbidity in critically ill patients. Procalcitonin (PCT) and C-reactive protein (CRP) are the most frequently used biomarkers in sepsis. We investigated changes in PCT and CRP concentrations in critically ill patients with sepsis to determine which biochemical marker better predicts outcome. We retrospectively analyzed 171 episodes in 157 patients with severe sepsis and septic shock who were admitted to the Samsung Medical Center intensive care unit from March 2013 to February 2014. The primary endpoint was patient outcome within 7 days from ICU admission (treatment failure). The secondary endpoint was 28-day mortality. Severe sepsis was observed in 42 (25%) episodes from 41 patients, and septic shock was observed in 129 (75%) episodes from 120 patients. Fifty-five (32%) episodes from 42 patients had clinically-documented infection, and 116 (68%) episodes from 99 patients had microbiologically-documented infection. Initial peak PCT and CRP levels were not associated with treatment failure and 28-day mortality. However, PCT clearance (PCTc) and CRP (CRPc) clearance were significantly associated with treatment failure (p = 0.027 and p = 0.030, respectively) and marginally significant with 28-day mortality (p = 0.064 and p = 0.062, respectively). The AUC for prediction of treatment success was 0.71 (95% CI, 0.61-0.82) for PCTc and 0.71 (95% CI, 0.61-0.81) for CRPc. The AUC for survival prediction was 0.77 (95% CI, 0.66-0.88) for PCTc and 0.77 (95% CI, 0.67-0.88) for CRPc. Changes in PCT and CRP concentrations were associated with outcomes of critically ill septic patients. CRP may not be inferior to PCT in predicting outcome in these patients.
脓毒症是重症患者死亡和发病的主要原因。降钙素原(PCT)和C反应蛋白(CRP)是脓毒症中最常用的生物标志物。我们研究了脓毒症重症患者中PCT和CRP浓度的变化,以确定哪种生化标志物能更好地预测预后。我们回顾性分析了2013年3月至2014年2月入住三星医疗中心重症监护病房的157例严重脓毒症和脓毒性休克患者的171次发病情况。主要终点是入住ICU后7天内的患者预后(治疗失败)。次要终点是28天死亡率。41例患者的42次发病(25%)观察到严重脓毒症,120例患者的129次发病(75%)观察到脓毒性休克。42例患者的55次发病(32%)有临床记录的感染,99例患者的116次发病(68%)有微生物学记录的感染。初始PCT和CRP峰值水平与治疗失败和28天死亡率无关。然而,PCT清除率(PCTc)和CRP清除率(CRPc)与治疗失败显著相关(分别为p = 0.027和p = 0.030),与28天死亡率边缘显著相关(分别为p = 0.064和p = 0.062)。PCTc预测治疗成功的AUC为0.71(95%CI,0.61 - 0.82),CRPc为0.71(95%CI,0.61 - 0.81)。PCTc预测生存的AUC为0.77(95%CI,0.66 - 0.88),CRPc为0.77(95%CI,0.67 - 0.88)。PCT和CRP浓度的变化与脓毒症重症患者的预后相关。在预测这些患者的预后方面,CRP可能并不逊色于PCT。